文献速递白血病

慢性髓性白血病成功实现无治疗缓解与免疫抑制细胞减少及自然杀伤细胞增加相关

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
PubMed 文献 · Br J Haematol · 2020-04-30

研究在CML8和CML10临床研究的酪氨酸激酶抑制剂停药时点刻画效应与抑制性免疫反应,发现达到无治疗缓解(TFR)的患者自然杀伤(NK)细胞活化受体表达升高,而FoxP3+调节性T细胞(Treg)和单核细胞型髓源性抑制细胞(Mo-MDSC)减少;基于CML10发现队列构建的预测模型在独立CML8队列中验证,高危组较低危组更易复发。

要点

  • 达到TFR的患者NK细胞活化受体表达升高,CD4+或CD8+ T细胞比例无差异。
  • TFR患者FoxP3+ Treg和Mo-MDSC concomitantly减少,效应与抑制免疫臂协同。
  • 基于NK细胞、Treg和Mo-MDSC绝对计数构建的效应-抑制评分可预测TFR成功。

核心结论

  • 在TKI停药时点,效应与抑制免疫反应共同参与成功TFR的免疫生物学,基于NK细胞、Treg和Mo-MDSC绝对计数的效应-抑制评分可有效预测TFR成功。

研究设计与样本

  • 研究利用CML8和CML10临床研究中TKI停药患者的样本,刻画效应与抑制性免疫反应;CML10作为发现队列用逻辑回归构建预测模型,并在独立CML8队列中验证。

主要发现

  • 达到TFR的患者中表达活化NK受体的自然杀伤(NK)细胞较高。
  • TFR患者与未达到TFR者相比,CD4+或CD8+ T细胞比例无差异。
  • TFR患者中FoxP3+调节性T细胞(Treg)和单核细胞型髓源性抑制细胞(Mo-MDSC) concomitantly减少。
  • 在CML10发现队列中,高危组较低危组更易复发(HR 7.4,95% CI 2.9-19.1)。
  • 模型在独立CML8队列中验证成功(HR 8.3,95% CI 2.2-31.3)。

关键数值与推荐

  • 效应-抑制评分使用TKI停药时的绝对NK细胞、Treg和Mo-MDSC计数计算。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is currently no biomarker that reliably predicts treatment-free remission (TFR) in chronic myeloid leukaemia (CML). We characterised effector and suppressor immune responses at the time of tyrosine kinase inhibitor (TKI) cessation in patients from the CML8 and CML10 clinical studies. Natural killer (NK) cells with increased expression of activating NK receptors were higher in patients who achieved TFR. There was no difference in the proportion of CD4+ or CD8+ T cells. Furthermore, we found that FoxP3+ regulatory T cells (T reg) and monocytic myeloid-derived suppressor cells (Mo-MDSCs) were concomitantly decreased in TFR patients, suggesting that the effector and suppressor arms of the immune system work in concert to mediate TFR. A discovery cohort (CML10) was used to generate a predictive model, using logistic regression. Patients classified into the high-risk group were more likely to relapse when compared with the low-risk group (HR 7·4, 95% CI 2·9-19·1). The model was successfully validated on the independent CML8 cohort (HR 8·3, 95% CI 2·2-31·3). Effective prediction of TFR success may be obtained with an effector-suppressor score, calculated using absolute NK cell, T reg, and Mo-MDSC counts, at TKI cessation, reflecting the contribution of both immune suppressors and effectors in the immunobiology underlying successful TFR.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020. PMID: 32352166. doi:10.1111/bjh.16718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。